Last reviewed · How we verify
SOTROVIMAB
At a glance
| Generic name | SOTROVIMAB |
|---|---|
| Modality | Monoclonal antibody |
| Phase | FDA-approved |
| First approval | 2021 |
Approved indications
Common side effects
Key clinical trials
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
- AGILE (Early Phase Platform Trial for COVID-19) (PHASE1, PHASE2)
- TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2
- COVID-19 International Drug Pregnancy Registry
- PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (PHASE2, PHASE3)
- COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2
- Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study (PHASE1)
- Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |